newsfilter
← Latest News
Business Wire·

AlloVir Reports First Quarter 2023 Financial Results

Company's three posoleucel Phase 3 global registrational trials for three distinct, first-to-market indications continue to enroll with data readouts on track for 2024 Positive results from a randomized, double-blind,